Clinical trial • Not applicable • Gastroenterology
Dabigatran etexilate for Colorectal polyps
Not applicable trial of Dabigatran etexilate for Colorectal polyps. None/Not specified-controlled. 686 participants.
Overview
- Trial Therapeutic Area
- Gastroenterology
- Trial Disease
- Colorectal polyps
- Trial Stage
- Not applicable
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 26-04-2024
- First CTIS Authorization Date
- 05-07-2024
Trial design
None/Not specified-controlled Not applicable trial in Spain.
- Comparator
- None/Not specified
- Target Sample Size
- 686
- Trial Duration For Participant
- 30
Eligibility
Recruits 686 No vulnerable population selected; participants are adults (18-80). Subject information and informed consent form documents are listed in the trial documents, but specific assent/consent handling details are not available in the provided metadata..
- Pregnancy Exclusion
- Pregnancy or breastfeeding
- Vulnerable Population
- No vulnerable population selected; participants are adults (18-80). Subject information and informed consent form documents are listed in the trial documents, but specific assent/consent handling details are not available in the provided metadata.
Inclusion criteria
- {"criterion_text":"- Subjects between 18 and 80 years old for whom a colonoscopy has been requested for any indication\n- Subjects who are under chronic antiplatelet therapy (other than ASA) or anticoagulant treatment."}
Exclusion criteria
- {"criterion_text":"- Coronary stent implantation in the previous 6 months or double antiplatelet therapy.\n- Severe comorbility (ASA >3)\n- Decompensated liver cirrhosis\n- Express refusal to participate in the study.\n- Cardiovascular or thromboembolic event (ischemic heart disease, cerebrovascular event, venous thromboembolic disease) in the previous 6 months.\n- Combined treatment with anticoagulants and antiplatelets\n- Chronic kidney disease grade 4 or higher, defined as a Creatinine clearance less than 30 ml/min.\n- Pregnancy or breastfeeding\n- Hemodialysis\n- Thrombophilia or known clotting disorders. Thrombopenia < 50000 platelets/mm3.\n- Urgent colonoscopy"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Significant post-polypectomy hemorrhage","definition_or_measurement_approach":""}
Recruitment
- Planned Sample Size
- 686
- Recruitment Window Months
- 28
- Consent Approach
- Informed consent to be obtained using the provided Subject information and informed consent form documents (listed in the trial documents as L1_SIS and ICF ...). Participants are adults (18-80) and therefore consent is provided by the participant. Specific text of consent/assent procedures and available languages are not provided in the metadata, though consent documents in Spanish are listed.
Geography
- Total Number Of Sites
- 16
- Total Number Of Participants
- 686
Spain
- Earliest CTIS Part Ii Submission Date
- 02-07-2024
- Latest Decision Or Authorization Date
- 02-03-2026
- Processing Time Days
- 608
- Number Of Sites
- 16
- Number Of Participants
- 686
Sites
- Site Name
- Hospital Germans Trias I Pujol
- Department Name
- Digestive system
- Principal Investigator Name
- Laura González
- Principal Investigator Email
- glaug2@gmail.com
- Contact Person Name
- Laura González
- Contact Person Email
- glaug2@gmail.com
- Site Name
- Hospital De La Santa Creu I Sant Pau
- Department Name
- Digestive system
- Principal Investigator Name
- Carlos Guarner
- Principal Investigator Email
- cguarnera@santpau.cat
- Contact Person Name
- Carlos Guarner
- Contact Person Email
- cguarnera@santpau.cat
- Site Name
- Hospital General Universitario San Jorge
- Department Name
- Digestive system
- Principal Investigator Name
- Santos Santolaria
- Principal Investigator Email
- ssantolariap@gmail.com
- Contact Person Name
- Santos Santolaria
- Contact Person Email
- ssantolariap@gmail.com
- Site Name
- Hospital General Universitario De Elche
- Department Name
- Digestive system
- Principal Investigator Name
- Alicia Brotons
- Principal Investigator Email
- aliciabbrotons@gmail.com
- Contact Person Name
- Alicia Brotons
- Contact Person Email
- aliciabbrotons@gmail.com
- Site Name
- Hospital Unviersitario Miguel Servet
- Department Name
- Digestive system
- Principal Investigator Name
- Raquel Vicente
- Principal Investigator Email
- raquelvicentelidon@gmail.com
- Contact Person Name
- Raquel Vicente
- Contact Person Email
- raquelvicentelidon@gmail.com
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Digestive system
- Principal Investigator Name
- Juan Antonio Serrano
- Principal Investigator Email
- juanantonio.serrano@salud.madrid.org
- Contact Person Name
- Juan Antonio Serrano
- Contact Person Email
- juanantonio.serrano@salud.madrid.org
- Site Name
- Hospital Obispo Polanco
- Department Name
- Digestive system
- Principal Investigator Name
- Inés Ariño
- Principal Investigator Email
- arino.ines@gmail.com
- Contact Person Name
- Inés Ariño
- Contact Person Email
- arino.ines@gmail.com
- Site Name
- Hospital General Universitario Dr. Balmis
- Department Name
- Digestive system
- Principal Investigator Name
- Rodrigo Jover
- Principal Investigator Email
- rodrigojover@gmail.com
- Contact Person Name
- Rodrigo Jover
- Contact Person Email
- rodrigojover@gmail.com
- Site Name
- Hospital Ernest Lluch
- Department Name
- Digestive system
- Principal Investigator Name
- Viviana Laredo
- Principal Investigator Email
- vlaredodelatorre@gmail.com
- Contact Person Name
- Viviana Laredo
- Contact Person Email
- vlaredodelatorre@gmail.com
- Site Name
- Hospital Santa Bárbara
- Department Name
- Digestive system
- Principal Investigator Name
- Celia del Caño
- Principal Investigator Email
- celiaccerdan@hotmail.com
- Contact Person Name
- Celia del Caño
- Contact Person Email
- celiaccerdan@hotmail.com
- Site Name
- Hospital Clinico Universitario Lozano Blesa
- Department Name
- Digestive system
- Principal Investigator Name
- Carlos Sostres
- Principal Investigator Email
- carlossostres@gmail.com
- Contact Person Name
- Carlos Sostres
- Contact Person Email
- carlossostres@gmail.com
- Site Name
- Hospital Royo Villanova
- Department Name
- Digestive system
- Principal Investigator Name
- Patricia Sanz
- Principal Investigator Email
- patricia.sanz.segura@gmail.com
- Contact Person Name
- Patricia Sanz
- Contact Person Email
- patricia.sanz.segura@gmail.com
- Site Name
- Hospital Comarcal Alcañiz
- Department Name
- Digestive system
- Principal Investigator Name
- Marina Solano
- Principal Investigator Email
- dramarinas@gmail.com
- Contact Person Name
- Marina Solano
- Contact Person Email
- dramarinas@gmail.com
- Site Name
- Hospital Universitario De Cabueñes
- Department Name
- Digestive system
- Principal Investigator Name
- Javier Tejedor
- Principal Investigator Email
- jtejedor1991@gmail.com
- Contact Person Name
- Javier Tejedor
- Contact Person Email
- jtejedor1991@gmail.com
- Site Name
- Hospital Universitario Donostia
- Department Name
- Digestive system
- Principal Investigator Name
- Maria Vaamonde
- Principal Investigator Email
- maria.lorv@gmail.com
- Contact Person Name
- Maria Vaamonde
- Contact Person Email
- maria.lorv@gmail.com
- Site Name
- Hospital Santos Reyes
- Department Name
- Digestive system
- Principal Investigator Name
- Luis Hernández
- Principal Investigator Email
- luishernandezvillalba@gmail.com
- Contact Person Name
- Luis Hernández
- Contact Person Email
- luishernandezvillalba@gmail.com
Sponsor
Primary sponsor
- Full Name
- Fundacion Instituto De Investigacion Sanitaria Aragon
- Organisation Type
- Laboratory/Research/Testing facility
- Country Of Registered Address
- Spain
Investigational products
- Investigational Product Name
- DABIGATRAN ETEXILATE
- Active Substance
- Dabigatran etexilate
- Modality
- Small molecule
- Routes Of Administration
- Oral
- Route
- Oral
- Maximum Dose
- 300 mg
- Investigational Product Name
- CLOPIDOGREL
- Active Substance
- Clopidogrel
- Modality
- Small molecule
- Routes Of Administration
- Oral
- Route
- Oral
- Maximum Dose
- 75 mg
- Investigational Product Name
- RIVAROXABAN
- Active Substance
- Rivaroxaban
- Modality
- Small molecule
- Routes Of Administration
- Oral
- Route
- Oral
- Maximum Dose
- 20 mg
- Investigational Product Name
- APIXABAN
- Active Substance
- Apixaban
- Modality
- Small molecule
- Routes Of Administration
- Oral
- Route
- Oral
- Maximum Dose
- 10 mg
- Investigational Product Name
- ACENOCOUMAROL
- Active Substance
- Acenocoumarol
- Modality
- Small molecule
- Routes Of Administration
- Oral
- Route
- Oral
- Maximum Dose
- 4 mg
- Investigational Product Name
- EDOXABAN
- Active Substance
- Edoxaban
- Modality
- Small molecule
- Routes Of Administration
- Oral
- Route
- Oral
- Maximum Dose
- 60 mg
Related trials
Other published trials that may interest you.